Epigenetic drivers of Prostate Cancer Bone Metastasis
We study how particular epigenetic modifiers can impact prostate cancer development and progression to bone metastasis, as well as how they might influence resistance to standard of care and experimental therapies.
Functional Identification of Therapeutic Vulnerabilities in mCRPC
We use unbiased, in vivo and genome-wide CRISPR screening approaches to indentify therapeutic vulnerabilities of the most aggressive, currently incurable prostate tumors.
For more information visit our lab website:
https://labs.icahn.mssm.edu/arriagalab/
Education
Bachelor's, University of Buenos Aires
PhD, University of Buenos Aires
Postdoctoral training, Columbia University
Honors & Awards
2022
NCI K22 Career Development Award to Promote Diversity
2021
Young Investigator Award, Prostate Cancer Foundation
2018
Dean’s Precision Medicine Research Fellowship, Columbia University
2017
Irving Institute Clinical Trials Office Pilot Award, Columbia University
2015
Postdoctoral Training Award, Department of Defense
2013
René Barón Foundation Award in Medical Sciences, National Academy of Medicine, Argentina
2009
CONICET Predoctoral fellowship, Ministry of Science, Argentina
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Arriaga has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Arriaga has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
